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Abstract Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right/left ventricular cardiomyopathy, cardiac amyloidosis, sarcoidosis, Chagas disease, and left ventricular noncompaction. The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. This expert consensus statement provides the clinician with guidance on evaluation and management of ACM and includes clinically relevant information on genetics and disease mechanisms. PICO questions were utilized to evaluate contemporary evidence and provide clinical guidance related to exercise in arrhythmogenic right ventricular cardiomyopathy. Recommendations were developed and approved by an expert writing group, after a systematic literature search with evidence tables, and discussion of their own clinical experience, to present the current knowledge in the field. Each recommendation is presented using the Class of Recommendation and Level of Evidence system formulated by the American College of Cardiology and the American Heart Association and is accompanied by references and explanatory text to provide essential context. The ongoing recognition of the genetic basis of ACM provides the opportunity to examine the diverse triggers and potential common pathway for the development of disease and arrhythmia.
KEYWORDS Arrhythmogenic cardiomyopathy; Arrhythmogenic left ventricular cardiomyopathy; Arrhythmogenic right ventricular cardiomyopathy; Cascade family screening; Catheter ablation; Diagnosis of arrhythmogenic cardiomyopathy; Disease mechanisms; Electrophysiology; Exercise restriction; Genetic testing; Genetic variants; ICD decisions; Left ventricular noncompaction; Risk stratification; Treatment of arrhythmogenic cardiomyopathy ABBREVIATIONS ACE 5 angiotensin-converting enzyme; ACM 5 arrhythmogenic cardiomyopathy; ALVC 5 arrhythmogenic left ventricular cardiomyopathy; ARB 5 angiotensin receptor blocker; ARVC 5 arrhythmogenic right ventricular cardiomyopathy; AV 5 atrioventricular; CMR 5 cardiac magnetic resonance imaging; COR 5 Class of Recommendation; DCM 5 dilated cardiomyopathy; ECG 5 electrocardiogram; EPS 5 electrophysiology study; ICD 5 implantable cardioverter defibrillator; LOE 5 Level of Evidence; LV 5 left ventricle; LVNC 5 left ventricular noncompaction; MET 5 metabolic equivalent; NSVT 5 nonsustained ventricular tachycardia; NYHA 5 New York Heart Association; 
Section 1 Introduction
This international consensus statement is intended to help cardiologists and other health care professionals involved in the care of adult and pediatric patients with arrhythmogenic cardiomyopathy (ACM), which encompasses a broad range of disorders, by providing recommendations for evaluation and management and supporting shared decision making between health care providers and patients in a document format that is also useful at the point of care. This consensus statement was written by experts in the field chosen by the Heart Rhythm Society (HRS) and collaborating organizations. Twelve societies collaborated with the HRS in this effort: the American College of Cardiology (ACC), the American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), the American Society of Echocardiography (ASE), the European Heart Rhythm Association (EHRA), the Heart Failure Society of America (HFSA), the International Society for Heart & Lung Transplantation (ISHLT), the Japanese Heart Rhythm Society (JHRS), the Latin American Heart Rhythm Society (LAHRS), the National Society of Genetic Counselors (NSGC), the Pediatric & Congenital Electrophysiology Society (PACES), and the Sociedade Brasileira de Arritmias Cardíacas (SOBRAC).
In accordance with the policies of the HRS, disclosure of any relationships with industry and other entities was required from the writing committee members (Appendix 1) and from all peer reviewers (Appendix 2). Of the 30 committee members, 16 (53%) had no relevant relationships with industry, including the document Chair and Vice-Chair. Sections that contain recommendations were written by committee members who were free of any relevant relationships with industry.
The writing committee reviewed evidence gathered by electronic literature searches (MEDLINE/PubMed, Embase, Cochrane Library). No specific year was chosen for the oldest literature. Search terms included but were not limited to the following: arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, dilated cardiomyopathy, lamin, ventricular tachycardia, ventricular arrhythmia, Fabry, noncompaction, phospholamban, cardiac amyloidosis, amyloid heart, heart failure, right ventricular failure, ARVC therapy, ARVC amiodarone, ARVC sotalol, ARVC flecainide, ablation, family screening, family risk, family member, relative, and electrocardiography. Evidence tables were constructed to describe the evidence, including study type, with observational cohorts representing the predominant form of evidence. Case reports were not used to support recommendations. This document also used a PICO question to focus the search for evidence in section 3.7. A member of the writing committee, free of relationships with industry and educated in evidence-based medicine and clinical practice document methodology, oversaw the evaluation of the evidence and determination of the Level of Evidence (LOE) for each recommendation.
Recommendations were formulated using the Class of Recommendation (COR) and LOE system formulated by the ACC and AHA (Figure 1) . This system provides a transparent mechanism to judge benefit relative to risk using a classification scheme (I, IIa, IIb, and III), supported by evidence quality and quantity using an LOE rating (A, B-R, B-NR, C-LD, C-EO); all recommendations are listed with a COR and LOE rating. For clarity and usefulness, each recommendation contains the specific references from the literature used to justify the LOE rating, which are also summarized in the evidence tables (Appendix 3). Recommendations based solely on the writing committee opinion are given an LOE rating of C-EO. Each recommendation is accompanied by explanatory text or knowledge "byte." Flow diagrams and appropriate tables provide a summary of the recommendations, intended to assist health care providers at the point of care. A comprehensive discussion (Section 4) is presented to further the understanding of molecular mechanisms underlying ventricular dysfunction and arrhythmogenesis in ACM. For additional information on HRS clinical practice document development, please refer to the HRS methodology manual. 1 Clinical practice documents that are relevant to this document are listed in Table 1 .
To reach consensus, the writing committee members participated in surveys, requiring a predefined threshold of 75% approval for each recommendation, with a quorum of two-thirds of the writing committee. An initial failure to reach consensus was resolved by subsequent discussions, revisions as needed, and re-voting. The mean consensus over all recommendations was 94%.
An industry forum was conducted to achieve a structured dialogue to address technical questions and gain a better understanding of future directions and challenges. Because of the potential for actual or perceived bias, HRS imposes strict parameters for information sharing to ensure that industry participates only in an advisory capacity and has no role in either the writing or review of the document. This consensus statement underwent internal review by the HRS Scientific and Clinical Documents Committee and was approved by the writing committee. Public comment on recommendations was obtained. The document underwent external peer review by reviewers appointed by HRS and each of the collaborating societies, and revisions were made by the chairs.
Section 2 Arrhythmogenic cardiomyopathy
ACM refers to an arrhythmogenic disorder of myocardium not secondary to ischemic, hypertensive, or valvular heart disease. In this expert consensus statement, ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right ventricular cardiomyopathy (ARVC), arrhythmogenic left ventricular cardiomyopathy (ALVC), ion channel abnormalities, amyloidosis, and left ventricular noncompaction (LVNC). The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy (DCM), with arrhythmia presentation accompanied by ventricular dilatation and/or impaired systolic function. ACM is a type of hereditary cardiovascular disease that demonstrates a "final common pathway" with genetic heterogeneity but similar phenotypes resulting from abnormalities in genes encoding proteins of similar function or genes encoding proteins participating in a common pathway cascade.
The top ten take-home messages based on novel concepts and Class I recommendations for ACM are as follows: 1) ACM is an inclusive designation referring to an arrhythmogenic disorder of myocardium characterized by a clinical presentation with documented and/or symptomatic arrhythmia as a distinguishing feature. 2) Genetic testing is indicated for all disease-associated genes and variants in patients and decedents. 3) Genetic counseling with a comprehensive 3-generation family history should be performed. 4) Clinical evaluation including electrocardiogram (ECG), cardiac imaging, and ambulatory monitoring is recommended for first-degree relatives every 1-3 years beginning at 10-12 years of age. 5) Implantable cardioverter defibrillator (ICD) placement for primary and secondary prevention of sudden cardiac death is recommended in individuals with ACM who have suffered a cardiac arrest with ventricular tachycardia (VT) or ventricular fibrillation (VF), in individuals with ACM who have sustained VT not hemodynamically tolerated, in individuals with ACM and LVEF 35% or lower and NYHA class II-III symptoms and an expected meaningful survival of greater than 1 year, and in individuals with ACM not due to ARVC and hemodynamically tolerated VT. 6) A shared decision-making approach to ICD placement should be used. 7) Beta-blocker therapy should be used for sinus tachycardia, supraventricular arrhythmias, atrial fibrillation, or atrial flutter with ventricular rates resulting in ICD therapy. 8) For exercise with ARVC, clinicians should counsel adolescent and adult individuals with a positive genetic test for ARVC but who are phenotype-negative that competitive or frequent high-intensity endurance exercise is associated with increased likelihood of developing ARVC and ventricular arrhythmias. 9) For cardiac amyloidosis, symptomatic and asymptomatic individuals with cardiac amyloidosis and second-degree AV block type II, high-grade AV block or third-degree AV block, should receive a permanent pacemaker, and individuals with cardiac amyloidosis who have survived a cardiac arrest, should receive an ICD if meaningful survival greater than 1 year is expected. 10) In individuals with LVNC, if the proband has a diseasecausing gene variant, it is recommended that first-degree relatives undergo clinical screening for the disease along with genetic counseling and genetic testing. ICD implantation is recommended in individuals with LVNC if there is evidence of ventricular tachyarrhythmias associated with syncope or resuscitated sudden death and if meaningful survival greater than 1 year is expected, and anticoagulation is recommended in individuals with LVNC if there is atrial fibrillation and/or previous embolic events.
This section discusses the features and presentation of ACM ( Figure 2, Figure 3 , and Figure 4 ), ARVC, ALVC, and the final common pathways in ACM ( Figure 5 and Figure 18 ), where with similar phenotypes and genetic heterogeneity will occur due to abnormalities in genes encoding proteins of similar function or genes encoding proteins participating in a common pathway cascade. 
Section 2.2 Final common pathways in arrhythmogenic cardiomyopathy

Section 3 Diagnosis and treatment of arrhythmogenic cardiomyopathy
This section covers the diagnosis and evaluation of ACM. The modified Task Force Criteria for ARVC ( Figure 6 ) is discussed. ECG features in ARVC including repolarization abnormalities (Figure 7 ), depolarization and conduction abnormalities of epsilon wave and prolonged terminal activation duration (Figure 8 ), ECG abnormalities in ACM other than ARVC, ambulatory ECG monitoring, and signalaveraged ECG. Cardiac imaging, electrophysiology testing, and endomyocardial biopsy to diagnose ACM are also covered. Genetic testing for the diagnosis and management of ARVC and other ACMs is discussed in detail including variant and gene interpretation ( Table 2) , choice of genetic test (Table 3) , advantages and disadvantages of various methods for screening genes (Table 4) , recommendations for who to study, and the role of genetic testing in ACM. Within genetic testing, the use of genetic testing for ACM risk stratification and management includes the topics of left ventricular (LV) dysfunction, multiple variants, and the specific genes and variants for which there is evidence for a clinically actionable relationship between genotype and phenotype. The specific genes and variants covered are desmosomal genes (Figure 9 ), lamin A/C (LMNA), desmoplakin (DSP), Transmembrane Protein 43 (TMEM43), and phospholamban (PLN). Limitations of genetic testing are also discussed, and a genetic testing recommendation flow chart is provided ( Figure 10 ). Cascade family screening considerations for ACM, including family history, cardiac evaluation, age-related penetrance of disease in at-risk relatives, cascade cardiac investigations, and cascade genetic testing in adults and minors are presented with recommendations and a recommendation flow chart ( Figure 11 ). Treatment considerations for ACM begin with a discussion of risk stratification and ICD decisions with recommendations and a flow chart ( Figure 12 ). Management of ventricular arrhythmia and dysfunction, including angiotensinconverting enzyme (ACE) inhibitors, beta-blockers, and antiarrhythmic drugs, is discussed in terms of medical therapies for LV failure, medical therapies for right ventricular (RV) failure, antithrombotic therapy in ACM, and arrhythmia management. Medical therapy recommendation flow charts are shown in Figures 13 and 14 . The role of catheter ablation in ACM with recommendations and a recommendation flow chart ( Figure 15 ) is discussed. Finally, the prevention of disease progression is presented in terms of exercise restrictions for ARVC. The clinical exercise questions used to direct the literature search are included, and also exercise definitions, exercise increasing age-related penetrance among genotype-positive relatives, exercise for carriers of pathogenic variants detected incidentally, exercise and relatives of "gene-elusive" patients with ARVC, exercise increasing arrhythmic risk and structural dysfunction in patients with ARVC, and exercise and other ACMs are discussed. Exercise restriction recommendations are included with a recommendation flow chart ( Figure 16 ), and the metabolic equivalents (METs) associated with common types of endurance exercise ( Figure 17 ).
Diagnosis and evaluation of arrhythmogenic cardiomyopathy
3.1.1 Evaluation overview Major Minor
Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole):
c) FracƟonal area change >33 to ≤40%
Regional RV akinesia or dyskinesia or dyssynchronous RV contracƟon and 1 of the following:
Regional RV akinesia or dyskinesia or dyssynchronous RV contracƟon and 1 of the following: These genes have multiple lines of evidence indicating involvement in ACM and its subtypes (arrhythmogenic left ventricular cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy). OR/EF and Signal:Background data are largely derived from cohorts with western European ancestry, and other ethnicities can be different.
AV 5 atrioventricular; BV 5 biventricular; Ca 5 calcium handling; CD 5 conduction delay; CHD 5 congenital heart disease; CPVT 5 catecholaminergic polymorphic ventricular tachycardia; DES 5 desmin; Desm 5 desmosomal; DSC2 5 desmocollin-2; DSG2 5 desmoglein-2; EF 5 etiological fraction; IF 5 intermediate filament; LD 5 left dominant; NA 5 data not available; NE 5 nuclear envelope; ns 5 not significant; NT 5 nontruncating variants; OR 5 odds ratio; RD 5 right dominant; SND 5 sinus node dysfunction; T 5 truncating variants. *Genes with significant excess in cases over ExAc reference samples. 17 Other genes that have been identified in ACM with insufficient or conflicting evidence are: ABCC9, 18 TGFB3, 19 TTN, 20 CTNNA3, 21 CNVs 5 copy number variations; IE 5 inefficient (expensive for large amounts of sequencing but inexpensive for a small amount); NGS 5 next generation sequencing; WES 5 whole exome sequencing; WGS 5 whole genome sequencing; 11 5 very high; 1 5 high; 1/2 5 intermediate; 2 5 low; 2 2 5 very low. 
COR LOE Recommendations References
I C-EO
It is recommended that a genetic counselor or appropriately experienced clinician obtain a comprehensive 3-generation family history. Exercise stress testing (arrhythmia provocation) may be considered as a useful adjunct to cardiovascular evaluation (COR IIb, LOE C-LD).
COR
CARDIOVASCULAR AND GENETIC EVALUATION
In families with a variant classified as pathogenic, it may be reasonable for asymptomatic members of a family who do not have the familial variant and have a normal cardiovascular evaluation to be released from regular screening and educated to return if disease symptoms occur (COR IIb, LOE C-EO).
It is recommended that a genetic counselor or appropriately experienced clinician obtain a comprehensive 3-generation family history (COR I, LOEC-EO). Figure 6 ), proband status, 2 or more desmosomal variants. If both NSVT and PVC criteria are present, then only NSVT can be used.
Decision for an ICD
The decision to implant an ICD in an individual with ACM should be a shared decision between the patient and the physician, taking into account the risks and benefits of the ICD over the potential longevity of the patient (COR I, LOE C-EO). In individuals with ACM who have sustained VT not hemodynamically tolerated, an ICD is recommended (COR I, LOE B-NR).
Yes
No
Yes
In individuals with ACM (other than ARVC) and hemodynamically tolerated VT, an ICD is recommended (COR I, LOE B-NR).
In individuals with ACM and syncope suspected to be due to a ventricular arrhythmia, an ICD is reasonable (COR IIa, LOE B-NR).
In individuals with ARVC with hemodynamically tolerated sustained VT, an ICD is reasonable (COR IIa, LOE B-NR).
No
In individuals with phospholamban cardiomyopathy and LVEF <45% or NSVT, an ICD is reasonable (COR IIa, LOE B-NR).
Yes
In individuals with lamin A/C ACM and two or more of the following: LVEF <45%, NSVT, male sex, an ICD is reasonable (COR IIa, LOE B-NR).
No
In individuals with lamin A/C ACM and an indication for pacing, an ICD with pacing capabilities is reasonable (COR IIa, LOE C-LD).
In individuals with FLNC ACM and an LVEF <45%, an ICD is reasonable (COR IIa, LOE C-LD).
Yes ICD implantation may be reasonable for individuals with ARVC and two major, one major and two minor, or four minor risk factors for ventricular arrhythmia* (COR IIb, LOE B-NR).
ICD implantation is reasonable for individuals with ARVC and three major, two major and two minor, or one major and four minor risk factors for ventricular arrhythmia* (COR IIa, LOE B-NR).
Yes
In individuals with ACM with LVEF 35% or lower and NYHA class I symptoms and an expected meaningful survival of greater than 1 year, an ICD is reasonable (COR IIa, LOE B-R).
In individuals with ACM with LVEF 35% or lower and NYHA class II-III symptoms and an expected meaningful survival of greater than 1 year, an ICD is recommended (COR I, LOE B-R). In symptomatic individuals with ACM and RV dysfunction, the use of isosorbide dinitrate to reduce preload may be considered (COR IIb, LOE C-EO).
In individuals with ACM and symptomatic RV dysfunction, the use of ACE inhibitors or ARBs, as well as beta-blockers, aldosterone antagonists, and diuretics, is reasonable (COR IIa, LOE C-EO). C-LD IIb C-LD Flecainide in combination with beta-blockers and in the absence of other antiarrhythmic drugs may be reasonable in individuals with ACM, an ICD, and preserved LV and RV function for control of ventricular arrhythmias that are refractory to other therapies.
81
ICD?
Inappropriate ICD therapies?
Yes Yes Symptomatic arrhythmias?
Beta-blocker therapy is recommended in ACM individuals with inappropriate ICD interventions resulting from sinus tachycardia, supraventricular tachycardia, or atrial fibrillation/flutter with high ventricular rate (COR I, LOE C-LD).
Beta-blocker therapy is reasonable in ACM individuals who do not have an ICD (COR IIa, LOE C-EO).
No
Preserved RV and LV function?
Continued symptoms due to ventricular arrhythmias?
Yes
Yes Flecainide in combination with beta-blockers and in the absence of other antiarrhythmic drugs may be reasonable in individuals with ACM, an ICD, and preserved LV and RV function for control of ventricular arrhythmias that are refractory to other therapies (COR IIb, LOE C-LD).
Amiodarone (LOE B-NR) and sotalol (LOE C-LD) may be reasonable in individuals with ACM for control of arrhythmic symptoms or to reduce ICD shocks (COR IIb). 
82-92
IIa B-NR In individuals with ACM and recurrent symptomatic sustained VT in whom antiarrhythmic medications are ineffective or not tolerated, catheter ablation with availability of a combined endocardial/epicardial approach is reasonable. 86, [88] [89] [90] [91] [92] IIa C-EO In symptomatic individuals with ACM and a high burden of ventricular ectopy or nonsustained VT in whom beta-blockers and/or antiarrhythmic medications are ineffective or not tolerated, catheter ablation with availability of a combined endocardial/epicardial approach is reasonable. IIb C-LD Individuals with ACM and recurrent symptomatic sustained VT in whom medical therapy has not failed may be considered for catheter ablation. 86, 88, 90 Yes No Sustained monomorphic VT?
In individuals with ACM and recurrent sustained monomorphic VT who have failed or are intolerant of amiodarone, catheter ablation is reasonable for reducing recurrent VT and ICD shocks (COR IIa, LOE B-NR).
In individuals with ACM and recurrent symptomatic sustained VT in whom antiarrhythmic medications are ineffective or not tolerated, catheter ablation with availability of a combined endocardial/epicardial approach is reasonable (COR IIa, LOE B-NR).
In symptomatic individuals with ACM and a high burden of ventricular ectopy or nonsustained VT in whom beta-blockers and/or antiarrhythmic medications are ineffective or not tolerated, catheter ablation with availability of a combined endocardial/epicardial approach is reasonable (COR IIa, LOE C-EO).
Individuals with ACM and recurrent symptomatic sustained VT in whom medical therapy has not failed may be considered for catheter ablation (COR IIb, LOE C-LD 99, 100 Inverse association between intensity of exercise (METs) and recommended frequency of participation among patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Aiding patients and at-risk family members in making choices about participation in various types of exercise involves ongoing discussion and shared decision making. Based on data suggesting that higher exercise intensity and doses (intensity*duration) are associated with poorer outcomes, 93, 96, 97, 101 vigorous-intensity activities (red/orange) should be performed rarely if at all, and lower-intensity activities (green) more regularly. This figure is provided to aid the clinician in understanding METs associated with a variety of common activities 99 and to aid in discussions with patients and families.
Section 4 Disease mechanisms
This section presents an overview of the basic science details of the mechanisms responsible for the forms of ACM (Figure 18 ). Desmosomal defects, ion channel defects, sarcomeric defects, metabolic defects, mitochondrial forms, and histiocytoid (oncocytic) cardiomyopathy are discussed.
Section 5 Other disorders
This section discusses other disorders of ACM, including amyloidosis, Brugada syndrome, potassium channels (KCNQ1, KCNH2, and TRMP4), phospholamban, and LVNC. Recommendations for amyloidosis arrhythmia treatment are presented with a flow chart ( Figure 19 ). LVNC diagnostic methods, diagnostic criteria (Table 5) , and treatment are discussed in detail including recommendations and flow charts for diagnosis ( Figure 20 ) and treatment ( Figure 21 ). 
Cardiac amyloidosis
In both symptomatic and asymptomatic individuals with cardiac amyloidosis and second-degree AV block type II, high-grade AV block or third-degree AV block, a permanent pacemaker is recommended (COR I, LOE B-NR).
Second-degree type II, high-grade or third-degree AV block?
Atrial arrhythmias? Survived cardiac arrest?
In individuals with cardiac amyloidosis who have survived a cardiac arrest, an ICD is recommended if meaningful survival greater than 1 year is expected (COR I, LOE C-EO).
AL-type with nonsustained ventricular arrhythmias?
In individuals with cardiac amyloidosis, the use of digoxin may be considered if used with caution due to the high risk of toxicity (COR IIb, LOE B-NR).
In individuals with cardiac amyloidosis and symptomatic atrial arrhythmias, the use of sotalol, dofetilide, or amiodarone may be considered (COR IIb, LOE C-EO).
In individuals with AL-type cardiac amyloidosis with nonsustained ventricular arrhythmias, a prophylactic ICD may be considered if meaningful survival greater than 1 year is expected (COR IIb, LOE B-NR).
In individuals with cardiac amyloidosis and symptomatic atrial arrhythmias, cardiac ablation may be considered (COR IIb, LOE C-LD). IIb C-LD In individuals with cardiac amyloidosis and symptomatic atrial arrhythmias, cardiac ablation may be considered.
Yes Yes Yes Yes
108
IIb C-EO In individuals with cardiac amyloidosis and symptomatic atrial arrhythmias, the use of sotalol, dofetilide, or amiodarone may be considered.
Amyloidosis
COR LOE Recommendations References
I B-NR
If the proband has a disease-causing gene variant, it is recommended that firstdegree relatives of individuals with LVNC undergo clinical screening for the disease along with genetic counseling and genetic testing.
109-111
I B-NR ICD implantation is recommended in individuals with LVNC and evidence of ventricular tachyarrhythmias associated with syncope or resuscitated sudden death if meaningful survival greater than 1 year is expected.
112
I B-NR Anticoagulation is recommended in individuals with LVNC with atrial fibrillation and in those with previous embolic events. 113 IIa B-NR In individuals with the clinical diagnosis of pathologic LVNC, genetic counseling and genetic testing are reasonable for diagnosis and for gene-specific targeted cascade family screening.
109,111
IIa B-NR ICD implantation is reasonable in individuals with LVNC and evidence of nonsustained VT associated with a reduced ejection fraction.
112,114
IIb B-NR Anticoagulation may be reasonable in individuals with LVNC with evidence of ventricular dysfunction.
113
IIb B-NR In individuals with suspected LVNC, the diagnostic criteria by echocardiography or cardiac magnetic resonance imaging (CMR), measured as the maximal ratio of noncompaction to compaction (NC/C), may be reasonable for establishing a diagnosis.
115-119
IIb B-NR In individuals with suspected LVNC and ventricular arrhythmias, CMR or other advanced cardiac imaging may be reasonable for establishing a diagnosis and for risk stratification. Total LV trabeculated mass without papillary muscles. End-diastolic NC layer volume .20%
118-120
C 5 compaction; CM 5 compacted myocardium; echo 5 echocardiogram; LV 5 left ventricle; MRI 5 magnetic resonance imaging; NC/C 5 maximum noncompaction to compaction ratio; NCM 5 noncompacted myocardium.
In individuals with the clinical diagnosis of pathologic LVNC, genetic counseling and genetic testing are reasonable for diagnosis and for gene-specific targeted cascade family screening (COR IIa, LOE B-NR).
If the proband has a disease-causing gene variant, it is recommended that first-degree relatives of individuals with LVNC undergo clinical screening for the disease along with genetic counseling and genetic testing (COR I, LOE B-NR).
In individuals with suspected LVNC and ventricular arrhythmias, CMR or other advanced cardiac imaging may be reasonable for establishing a diagnosis and for risk stratification (COR IIb, LOE B-NR).
Diagnosis of LVNC Genetic evaluation of LVNC
Ventricular arrhythmias?
Patient suspected of LVNC?
In individuals with suspected LVNC, the diagnostic criteria by echocardiography or CMR, measured as the maximal ratio of noncompaction to compaction (NC/C), may be reasonable for establishing a diagnosis (COR IIb, LOE B-NR). e396 Heart Rhythm, Vol 16, No 11, November 2019 Anticoagulation is recommended in individuals with LVNC with atrial fibrillation and in those with previous embolic events (COR I, LOE B-NR).
Yes
YES
Ventricular tachyarrhythmia with syncope or resuscitated from sudden death?
ICD implantation is reasonable in individuals with LVNC and evidence of nonsustained VT associated with a reduced ejection fraction (COR IIa, LOE B-NR).
Atrial fibrillation or prior embolic event?
Individuals with LVNC Nonsustained VT with a reduced ejection fraction present?
Ventricular dysfunction present?
Anticoagulation may be reasonable in individuals with LVNC with evidence of ventricular dysfunction (COR IIb, LOE B-NR).
No
Yes
Yes ICD implantation is recommended in individuals with LVNC and evidence of ventricular tachyarrhythmias associated with syncope or resuscitated sudden death if meaningful survival greater than 1 year is expected (COR I, LOE B-NR).
Yes Figure 21 Left ventricular noncompaction (LVNC) treatment recommendations. Anticoagulation refers to vitamin K antagonists and direct oral anticoagulants. Children are often administered aspirin. COR 5 Class of Recommendation; ICD 5 implantable cardioverter defibrillator; LOE 5 Level of Evidence; LVNC 5 left ventricular noncompaction; VT 5 ventricular tachycardia. Colors correspond to COR in Figure 1 .
